DE3483282D1 - Lang wirksame cefaclor-formulierung und deren herstellung. - Google Patents

Lang wirksame cefaclor-formulierung und deren herstellung.

Info

Publication number
DE3483282D1
DE3483282D1 DE8484303908T DE3483282T DE3483282D1 DE 3483282 D1 DE3483282 D1 DE 3483282D1 DE 8484303908 T DE8484303908 T DE 8484303908T DE 3483282 T DE3483282 T DE 3483282T DE 3483282 D1 DE3483282 D1 DE 3483282D1
Authority
DE
Germany
Prior art keywords
long
cefaclor
effective
production
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8484303908T
Other languages
German (de)
English (en)
Inventor
Teruo Sakamoto
Sadao Kawai
Kinzaburo Noda
Toyohiko Takeda
Hiroshi Kato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Application granted granted Critical
Publication of DE3483282D1 publication Critical patent/DE3483282D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE8484303908T 1983-06-15 1984-06-08 Lang wirksame cefaclor-formulierung und deren herstellung. Expired - Fee Related DE3483282D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP58108289A JPS601128A (ja) 1983-06-15 1983-06-15 作用持続型セフアクロル製剤

Publications (1)

Publication Number Publication Date
DE3483282D1 true DE3483282D1 (de) 1990-10-31

Family

ID=14480890

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8484303908T Expired - Fee Related DE3483282D1 (de) 1983-06-15 1984-06-08 Lang wirksame cefaclor-formulierung und deren herstellung.

Country Status (23)

Country Link
US (1) US4713247A (en:Method)
EP (1) EP0129382B1 (en:Method)
JP (1) JPS601128A (en:Method)
KR (1) KR910004573B1 (en:Method)
AT (1) ATE56869T1 (en:Method)
AU (1) AU568654B2 (en:Method)
BG (1) BG60261B2 (en:Method)
CA (1) CA1213218A (en:Method)
DD (1) DD216163A5 (en:Method)
DE (1) DE3483282D1 (en:Method)
DK (2) DK170922B1 (en:Method)
ES (1) ES533901A0 (en:Method)
FI (1) FI84556C (en:Method)
GB (1) GB2141342B (en:Method)
GR (1) GR81598B (en:Method)
HU (1) HU193434B (en:Method)
IE (1) IE58278B1 (en:Method)
IL (1) IL72083A (en:Method)
NZ (1) NZ208345A (en:Method)
PH (1) PH19902A (en:Method)
PT (1) PT78699B (en:Method)
RO (1) RO88924A (en:Method)
ZA (1) ZA844357B (en:Method)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229132A (en) * 1985-02-22 1993-07-20 Grimberg Georges Serge Non-absorbable gastrointestinal medicament provided for treating the two levels of the digestive tract at the same time
JPS61210025A (ja) * 1985-03-14 1986-09-18 Teisan Seiyaku Kk 安定化された抗生物質複合顆粒製剤
JPS62226926A (ja) * 1986-03-27 1987-10-05 Teisan Seiyaku Kk 持続性複合顆粒剤
AU591248B2 (en) * 1986-03-27 1989-11-30 Kinaform Technology, Inc. Sustained-release pharaceutical preparation
JPH0714863B2 (ja) * 1986-06-02 1995-02-22 忠生 白石 時差溶解性の入浴剤
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
BE1002079A4 (fr) * 1988-07-01 1990-06-19 S M B Lab Composition pharmaceutique d'erythromycine a liberation prolongee, sa preparation et son utilisation.
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5122384A (en) * 1989-05-05 1992-06-16 Kv Pharmaceutical Company Oral once-per-day organic nitrate formulation which does not induce tolerance
WO1991019486A1 (en) * 1990-06-14 1991-12-26 Kalmo Enterprises, Inc. Stable aqueous drug suspensions
GB9318641D0 (en) * 1993-09-08 1993-10-27 Edko Trading Representation Compositions
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
AU5107496A (en) * 1996-03-13 1997-10-01 Labtec Gesellschaft Fur Technologische Forschung Und Entwicklung Mbh Medicament preparation for angiotensin converting enzyme (ace)-inhibitors
US5948440A (en) * 1997-12-17 1999-09-07 Ranbaxy Laboratories Limited Modified release matrix formulation of cefaclor and cephalexin
ZA98728B (en) * 1998-01-29 1998-10-28 Ranbaxy Lab Ltd Modified release matrix formulations of cefactor and cephalexin
KR100296413B1 (ko) * 1998-04-01 2001-11-14 김선진 세파클러함유서방성정제
US20030170181A1 (en) * 1999-04-06 2003-09-11 Midha Kamal K. Method for preventing abuse of methylphenidate
EP1165054A4 (en) * 1999-04-06 2005-02-09 Pharmaquest Ltd PHARMACEUTICAL DOSAGE FORM FOR INTERMITTENT DELIVERY OF METHYLPHENIDATE
WO2000069417A1 (en) * 1999-05-14 2000-11-23 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
US6596307B1 (en) 1999-06-15 2003-07-22 Eli Lilly And Company Process for preparing pharmaceutical bulk material having uniform dissolution
CA2400818C (en) * 2000-02-24 2009-01-06 Advancis Pharmaceutical Corporation Antibiotic and antifungal compositions
US7025989B2 (en) * 2000-02-24 2006-04-11 Advancis Pharmaceutical Corp. Multiple-delayed released antibiotic product, use and formulation thereof
EP1257255A4 (en) * 2000-02-24 2008-07-30 Advancis Pharmaceutical Corp THERAPEUTIC PRODUCT, ITS USE AND MANUFACTURE
AU2001239869B2 (en) * 2000-02-24 2005-12-15 Shionogi, Inc. Antibiotic composition with inhibitor
US6991807B2 (en) * 2000-02-24 2006-01-31 Advancis Pharmaceutical, Corp. Antibiotic composition
CA2435305A1 (en) * 2001-01-18 2002-07-25 Natco Pharma Limited Extended release pharmaceutical compositions containing beta-lactam antibiotics
CA2478121A1 (en) * 2002-03-07 2003-09-18 Advancis Pharmaceutical Corporation Antibiotic composition
AU2003219184A1 (en) * 2002-05-09 2003-11-11 Diffucap-Chemobras Quimica E Farmaceutica, Ltda. Novel method of preparing programmed-release compositions containing (s)-1-(n-(1-(ethoxycarbonyl)-3-phenylpropyl)-l-alanyl)-l-proline and the product thus obtained
EP1648418A4 (en) * 2003-07-21 2011-11-16 Middlebrook Pharmaceuticals Inc ANTIBIOTIC PRODUCT, ITS USE AND FORMULATION
CA2533178C (en) * 2003-07-21 2014-03-11 Advancis Pharmaceutical Corporation Antibiotic product, use and formulation thereof
JP2006528190A (ja) * 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション 抗生物質製剤、その使用法及び作成方法
AU2004264356B2 (en) * 2003-08-12 2011-01-27 Shionogi, Inc. Antibiotic product, use and formulation thereof
JP5686494B2 (ja) * 2003-08-29 2015-03-18 シオノギ インコーポレイテッド 抗生物質製剤、その使用法及び作成方法
EP1663169A4 (en) * 2003-09-15 2010-11-24 Middlebrook Pharmaceuticals In ANTIBIOTICS, ITS USE AND FORMULATION
BR0318535A (pt) * 2003-09-30 2006-09-12 Lupin Ltd composição farmacêutica para o envio controlado de droga, processo para a preparação de uma composição farmacêutica e composição de liberação controlada
CN101184477A (zh) * 2005-04-12 2008-05-21 依兰药物国际有限公司 治疗细菌感染的含头孢菌素控释组合物
EP1890676A2 (en) 2005-06-02 2008-02-27 Novozymes A/S Blends of inactive particles and active particles
US20060287212A1 (en) * 2005-06-02 2006-12-21 Novozymes A/S Blends of inactive particles and active particles
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
HRP20170179T1 (hr) 2009-05-19 2017-04-07 Celgene Corporation Oblici 4-amino-2-(2,6-dioksopiperidin-3-il)izoindolin-1,3-diona
BR112014014805A2 (pt) * 2011-12-19 2017-06-13 Salix Pharmaceuticals Ltd processos para tratamento e prevenção de constipação induzida por opióide que utilizam composições orais de metilnaltrexona
CA3018328A1 (en) 2014-10-31 2016-04-30 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
CN104688701A (zh) * 2015-03-20 2015-06-10 江苏亚邦强生药业有限公司 一种头孢克洛片剂及其制备方法
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
CN110408670A (zh) * 2019-08-19 2019-11-05 苏州盛达药业有限公司 一种酶催化合成头孢克洛的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2738303A (en) * 1952-07-18 1956-03-13 Smith Kline French Lab Sympathomimetic preparation
US3906086A (en) * 1971-07-19 1975-09-16 Richard G Powers Timed-release aspirin
JPS52139713A (en) * 1976-05-13 1977-11-21 Shionogi & Co Ltd Sustained release cefalexin preparations
US4250166A (en) * 1977-05-27 1981-02-10 Shionogi & Co., Ltd. Long acting preparation of cefalexin for effective treatments of bacterial infection sensitive to cefalexin
GR74995B (en:Method) * 1980-08-27 1984-07-12 Ciba Geigy Ag
JPS5826816A (ja) * 1981-08-11 1983-02-17 Teisan Seiyaku Kk 球形顆粒からなる持続性複合顆粒剤

Also Published As

Publication number Publication date
PH19902A (en) 1986-08-13
KR850000242A (ko) 1985-02-26
DK291884A (da) 1984-12-16
DK170922B1 (da) 1996-03-18
GB2141342B (en) 1986-11-12
IE841444L (en) 1984-12-15
PT78699A (pt) 1985-01-01
DD216163A5 (de) 1984-12-05
JPS601128A (ja) 1985-01-07
PT78699B (en) 1986-07-15
NZ208345A (en) 1986-12-05
CA1213218A (en) 1986-10-28
EP0129382A3 (en) 1986-07-09
EP0129382A2 (en) 1984-12-27
ES8602407A1 (es) 1985-12-01
AU2941884A (en) 1984-12-20
AU568654B2 (en) 1988-01-07
JPS6232166B2 (en:Method) 1987-07-13
ATE56869T1 (de) 1990-10-15
IL72083A0 (en) 1984-10-31
DK291884D0 (da) 1984-06-14
KR910004573B1 (ko) 1991-07-06
BG60261B1 (bg) 1994-03-31
GR81598B (en:Method) 1984-12-11
RO88924A (ro) 1986-04-30
BG60261B2 (en) 1994-03-31
IE58278B1 (en) 1993-08-25
EP0129382B1 (en) 1990-09-26
FI842406A0 (fi) 1984-06-13
FI84556C (fi) 1991-12-27
IL72083A (en) 1987-10-30
ES533901A0 (es) 1985-12-01
GB2141342A (en) 1984-12-19
FI842406L (fi) 1984-12-16
GB8414633D0 (en) 1984-07-11
HUT34692A (en) 1985-04-28
HU193434B (en) 1987-10-28
US4713247A (en) 1987-12-15
ZA844357B (en) 1985-06-26
FI84556B (fi) 1991-09-13

Similar Documents

Publication Publication Date Title
DE3483282D1 (de) Lang wirksame cefaclor-formulierung und deren herstellung.
FI972967A0 (fi) Imidatso(4,5-c)kinoliiniamiineja
EP0279149A3 (en) Benzimidazole derivatives, process for their production and a pharmaceutical composition containing the same
HUT46654A (en) Process for producing substituted basic 2-amino-tetralin derivatives and pharmaceutical compositions comprising the same as active ingredient
HUT48609A (en) Process for producing kumaran derivatives and pharmaceutical compositions comprising same as active ingredient
ATE110745T1 (de) Wachstumshormonkristalle und verfahren zu deren herstellung.
HUT64013A (en) Process for producing hiv-inhibiting phenylacetamide derivatives and pharmaceutical compositions comprising such compounds as active ingredient
ES2002083A6 (es) Un metodo para preparar derivados de piroglutamida
ATE147757T1 (de) Propanolamin-cyclohexapeptide
HUT47124A (en) Process for producing pharmaceutical compositions comprising organic platinum complex as active ingredient and the active ingredients
SE8501532L (sv) Nya lekemedelskombinationer med synergistisk verkan och forfarande for deras framstellning
HUT49590A (en) Process for producing benzimidazole derivatives and pharmaceutical compositions comprising same as active ingredient
HUT47579A (en) Process for production of new imidazo /1,2-a/-pirimidins and their salts and medical compositions containing them as active substance
HUT62789A (en) Process for producing pharmaceutical composition comprising r(+)-3-amino-1-hydroxypyrroliden-2-one as active ingredient and suitable for treating anxiety
EP0132772A3 (en) Fr-900216 substance obtainable by cultivating atcc 20577 for use as an active therapeutic substance and pharmaceutical antitumor composition comprising fr-900216 substance
ATE124945T1 (de) 2,13-disubstituierte ergoline, deren herstellung und verwendung in arzneimitteln.
HUT50361A (en) Process for producing new antibiotic named kammunocyn and pharmaceutical compositions comprising this compound as active ingredient

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee